Sienabiotech, a drug discovery company with particular expertise in CNS disorders, uses software to capture, manage and integrate biological, chemical and inventory data
IDBS, provider of integrated data management, analysis and decision-making software for biopharmaceutical discovery research, reports that Sienabiotech will implement IDBS's ActivityBase suite.
Sienabiotech is a research-based drug discovery company with particular expertise in CNS disorders, operating across the spectrum of discovery activities from target identification to phase IIa clinical trials.
Sienabiotech will deploy ActivityBase in lead discovery to capture, manage and integrate biological, chemical and inventory data.
The company has chosen the ActivityBase inventory manager module (Aim) as part of its core data management system.
Since Aim and ActivityBase use the same data model, inventory and screening workflows are closely integrated.
Aim takes a somewhat less compound-centric approach than traditional inventory systems, enabling other samples, such as proteins and cells, to be managed with the same efficiency as compounds within the ActivityBase environment.
Georg Terstappen, vice president of discovery research at Sienabiotech commented: "The ActivityBase suite will facilitate our ambitious plans as it provides a scalable platform for managing inventory, screening and cheminformatic data.
"Furthermore, it will facilitate data exchange between biologists and chemists across the organisation thus providing a solid basis for maximum knowledge extraction.
"Our evaluations revealed that ActivityBase has the edge, both in terms of functionality and ease of use".
Neil Kipling, chairman and CEO of IDBS said, "Sienabiotech is among a growing number of companies adopting an integrated strategy for managing inventory and lead discovery data.
"We are very pleased to be working with Sienabiotech, at the leading edge of neurodegenerative CNS disorders, helping them put in place an informatics foundation for sustainable growth."
